Two lots of a drug for type 2 diabetes were recalled in the United States, due to possible contamination with a potentially carcinogenic compound.
The voluntary recall of metformin tablets, designed to lower glucose levels, comes after tests indicated the drug had high levels of a chemical considered a possible carcinogen.
These are batches MET200101 and MET200301, which expire in May 2022.